Arcutis Biotherapeutics Inc. (ARQT) carries a Roarable Rating of D+ (Sell) with 54/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $32.07 (+0.31% 1D, market cap $4.02B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 17/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, ARQT ranks #240 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ARQT carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of 90.2%, and ROIC of -3.0%. By comparison, LQDA (Liquidia Corporation) holds a D- grade (36/100 RQD, P/E N/A, ROIC -12.6%, cap $4.03B) and INDV (Indivior Pharmaceuticals Inc.) posts a D grade (51/100 RQD, P/E 19.8x, ROIC 62.2%, cap $4.16B). Among the 5-stock peer group, INDV leads on earnings multiple (19.8x) while INDV leads on capital efficiency (62.2% ROIC).
Per ARQT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001787306), Arcutis Biotherapeutics Inc. generated $376.1M in revenue (+91.3% YoY), -$16.1M in net income, and -$6.3M in free cash flow against $433.0M in total assets and $108.0M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±10.1% realized swing band)
Altman Z-Score 7.78 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 6/9
Dilution Drag (+1.64% YoY Shares) & executive Form 4 sales trim 14 pts from alignment
While ARQT currently carries a cautious 54/100 (D+) rating due to Insider Conviction & Share Dilution (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Big institutional funds and options desks are actively positioning on the bullish side.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($26.94) and Max Pain ($33.67) forces dealer call-delta covering toward $37.16.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Arcutis Biotherapeutics Inc. (ARQT) advanced +0.31% to $32.07, trading at 91% of its 52-week range ($19.3 – $33.3). Stretched risk/reward at current multiples (-3% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Arcutis Biotherapeutics Inc. (ARQT) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Arcutis Biotherapeutics Inc. (ARQT) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Arcutis Biotherapeutics Inc. (ARQT) market action, institutional positioning, and fundamental catalysts.
ChartMill report covering Arcutis Biotherapeutics Inc. (ARQT) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Arcutis Biotherapeutics Inc. (ARQT) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering Arcutis Biotherapeutics Inc. (ARQT) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Arcutis Biotherapeutics Inc. (ARQT) market action, institutional positioning, and fundamental catalysts.
Simply Wall Street report covering Arcutis Biotherapeutics Inc. (ARQT) market action, institutional positioning, and fundamental catalysts.
Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcutis Biotherapeutics (ARQT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +91.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ARQT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ARQT. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Arcutis Biotherapeutics Inc. (ARQT) ranks #240 by composite RQD confidence (54/100, grade D+) and #183 by equity capitalization ($4.02B). Within this direct 5-issuer industry benchmark cohort, INDV leads on earnings valuation at 19.8x trailing P/E, while INDV leads on capital efficiency and profitability with 62.2% ROIC and 80.2% gross margin. ARQT currently leads its immediate peer cohort in composite quantitative strength at 54/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ARQT
ACTIVE
Arcutis Biotherapeutics Inc. | D+ | 54/100 | — | 90.2% | -3.0% | +0.31% | $4.02B | Benchmark Subject |
| LQDA Liquidia Corporation | D- | 36/100 | — | — | -12.6% | +0.16% | $4.03B | /lqda-vs-arqt → |
| INDV Indivior Pharmaceuticals Inc. | D | 51/100 | 19.8x | 80.2% | 62.2% | +0.34% | $4.16B | /indv-vs-arqt → |
| EWTX Edgewise Therapeutics Inc. | D- | 41/100 | — | — | -31.9% | -0.03% | $4.23B | /ewtx-vs-arqt → |
| ABCL AbCellera Biologics Inc. | D- | 38/100 | — | — | -20.5% | -6.19% | $4.24B | /abcl-vs-arqt → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Arcutis Biotherapeutics Inc. (ARQT) reported GAAP revenue of $376.1M (+91.3% vs. FY2024 revenue of $196.5M , and +530.9% cumulative change since FY2023) , GAAP net income of -$16.1M, operating cash flow of -$5.6M, and free cash flow of -$6.3M (+94.4% YoY). On the balance sheet, ARQT closed FY2025 with $433.0M in total assets against $108.0M in total debt (Altman Z-Score: 7.78, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $376.1M | -$16.1M | -$5.6M | -$6.3M | $433.0M | $108.0M |
| FY2024 (FY) | 2024-12-31 | $196.5M | -$140.0M | -$112.2M | -$112.3M | $348.9M | $107.2M |
| FY2023 (FY) | 2023-12-31 | $59.6M | -$262.1M | -$247.1M | -$249.7M | $2.21B | $517.2M |
As of 2026-11-02, Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $32.07 (+0.31% 1D, market cap $4.02B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 17/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, ARQT ranks #240 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ARQT carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of 90.2%, and ROIC of -3.0%. By comparison, LQDA (Liquidia Corporation) holds a D- grade (36/100 RQD, P/E N/A, ROIC -12.6%, cap $4.03B) and INDV (Indivior Pharmaceuticals Inc.) posts a D grade (51/100 RQD, P/E 19.8x, ROIC 62.2%, cap $4.16B). Among the 5-stock peer group, INDV leads on earnings multiple (19.8x) while INDV leads on capital efficiency (62.2% ROIC).
Per ARQT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001787306), Arcutis Biotherapeutics Inc. generated $376.1M in revenue (+91.3% YoY), -$16.1M in net income, and -$6.3M in free cash flow against $433.0M in total assets and $108.0M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ARQT last traded at $32.07 (+0.31% on volume of 1,883,941 shares), positioning the stock +19.04% above its 50-day simple moving average ($26.94) and +26.71% above its 200-day simple moving average ($25.31). Across its 52-week range of $19.30 to $33.30, ARQT sits at the 91.2% percentile with a 14-day RSI of 65.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±10.1% ($28.83 to $35.31).
Why ARQT Stock advanced +0.31% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-3% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, ARQT scores 54 out of 100, a letter grade of D+, with the verdict label "Roarable Sell — Weak Fundamentals / Trim." Across the five pillars, the fundamental cash engine scores 9 of 20 (ROIC -3%; FCF yield -0.16%), indicating that current cash generation does not yet support the equity on a return-on-capital basis. Whale/13F flow scores 17 of 20 (institutional accumulation and options positioning), the strongest pillar and a signal of institutional interest. Insider conviction scores 6 of 20 (SEC Form 4 and Congressional PTR cluster flow), a weak reading. Macro regime fit scores 8 of 20 (Beta 1; sector sensitivity). Forensic balance sheet scores 14 of 20 (Altman Z 7.78; Piotroski F 6/9; Debt/Equity 0.57), a moderate reading.
For a prospective investor evaluating the stock today, the rating implies a clear tradeoff: institutional positioning is supportive, while the earnings and cash-flow base is negative and insider conviction is weak. Upside, per the rating's framework, would depend on the cash engine turning positive; the valuation tradeoff is that the forward P/E of 24 is being paid against negative trailing EPS of -0.13. The balance-sheet pillar offers some cushion, but the overall verdict is a weak-fundamentals reading.
Arcutis Biotherapeutics Inc. (ARQT) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry, per the company profile. The source data does not describe its specific products, customers, or revenue model. The financials show revenue of $376.1M for FY 2025, per the SEC financials. Gross margin is 90.2%, per the market data.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $376.1M | $-12.2M | $-16.1M | N/A | $-6.3M | $42.9M | $108.0M |
| FY 2024 | $196.5M | $-128.4M | $-140.0M | N/A | $-112.3M | $71.3M | $107.2M |
| FY 2023 | $59.6M | $-241.1M | $-262.1M | N/A | $-249.7M | N/A | $517.2M |
Per the SEC financials, the company reported losses in all three periods, though operating losses narrowed substantially from FY 2023 to FY 2025 and revenue grew across the series. Per the market data, the operating margin is -3.3%, the net margin is -4.3%, and ROIC is -3%. Per the Roarable RQD rating, the Altman Z-Score is 7.78 and the Piotroski F-Score is 6 of 9, with Debt/Equity of 0.57. The balance sheet posture, per these figures, shows debt of $108.0M against cash of $42.9M in FY 2025.
Per the recent news wire, six items relate to ARQT. Three are flagged RED "RISK WATCH" items (a Yahoo Finance piece questioning whether the stock is still below fair value following fresh ZORYVE data, a Seeking Alpha piece framing ARQT as an emerging GARP stock, and a Yahoo Finance clinical-data piece). A Benzinga item on a share surge is also flagged RED. Two items are flagged GREEN "CATALYST": a ChartMill piece on undervaluation supported by growth and margins, and a GuruFocus piece reporting shares rallying to a 52-week high amid strong momentum. Per the Butterfly Supply-Chain Graph, no supply-chain links or proprietary signals are available in the source data.
Per the Butterfly Supply-Chain Graph, supply chain status is NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore not available in source data. Investors should note that this absence means the rating cannot be traced through a supplier or customer network within the provided data.
Real-time company headlines, analyst actions, and sector developments for Arcutis Biotherapeutics Inc. (ARQT) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Arcutis Biotherapeutics Inc. (ARQT) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Arcutis Biotherapeutics Inc. (ARQT) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Arcutis Biotherapeutics Inc. (ARQT) market action, institutional positioning, and fundamental catalysts.
ChartMill report covering Arcutis Biotherapeutics Inc. (ARQT) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Arcutis Biotherapeutics Inc. (ARQT) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering Arcutis Biotherapeutics Inc. (ARQT) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Arcutis Biotherapeutics Inc. (ARQT) market action, institutional positioning, and fundamental catalysts.
Simply Wall Street report covering Arcutis Biotherapeutics Inc. (ARQT) market action, institutional positioning, and fundamental catalysts.
Welcome to the ARQT (Arcutis Biotherapeutics Inc.) Roar Pit. Current RQD Composite is 54/100 (Roarable Sell — Weak Fundamentals / Trim) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on ARQT, but look at what you are paying: current EV/EBITDA multiples with 90.2% gross margins. Unless Arcutis Biotherapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on ARQT, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $31.97 (52-wk range $19.30 - $33.30), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).